Enter Note Done
Go to previous page in this tab
Session
  • Presentation | General Poster Session - Saturday General Poster Session
  • General Poster Session
  • Share Icon
    Bookmark Icon
  • 2419-P - CNP-103: A First-in-Human Phase 1b/2a Study of an Antigen-Specific, Immune-Tolerizing Therapy for Recent-Onset Type 1 Diabetes  [Board No. 2419]
    • Schedule
    Notes
  • Poster Hall (Halls D-E)
    2419-P
    Set Timezone

S.K.Patel: None. P.M.Peloso: Employee; Current; COUR Pharma. J.Gaglia: Consultant; Current; Vertex Pharmaceuticals Incorporated, AstraZeneca, polTreg, Research Support; Current; Sanofi, Stock/Shareholder; Current; Vertex Pharmaceuticals Incorporated. T.M.Triolo: None. E.Hong: Employee; Current; Cour Pharmaceutical Development Company. M.Frey: Employee; Current; COUR Pharma. J.R.Podojil: None. D.P.Mccarthy: Employee; Current; COUR Pharmaceuticals. K.S.Cerosaletti: Consultant; Ended; Mozart Therapeutics, Other - Research collaboration supported by Breakthrough T1D grant funding; Ended; Base5 (Benthic) Genomics, Research Support; Current; Cour Pharmaceuticals, GentiBio, Inc, InduPro Therapeutics, Research Support; Ended; IM Therapeutics. A.Elhofy: None.
Type
Main Session